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Introduction
Laboratory monitoring of patients treated with 
isotretinoin is standard practice, but evaluation of 
the results is confounded by choice of laboratory test. 
In general the same tests as reported by the original 
investigators [1] are the ones used today in clinical 
practice. Numerous case reports documenting 
pancreatitis, liver damage, leukopenia, and 
thrombocytopenia [2] exist but the true incidence of 
clinically significant abnormalities is not known.
Results
A retrospective chart review was performed regarding 
patients treated with isotretinoin for acne between 
2005 and 2014. Two hundred forty-six patients were 
identified. Patient identity was protected by assigning 
a code number to each individual. Laboratory tests 
were done at initiation of therapy and with dosage 
changes. Patients with abnormalities had monthly 
testing until they resolved. Tests obtained were CBC, 
lipid panel, AST, ALT, CK, GGT, and C-reactive protein. 
Female patients also had HCG performed. None were 
positive.
Thirty-five patients had an elevated AST and 32 of 
these had an elevated CK; 32 had an elevated ALT 
and 11 of these had an elevated CK. Thirteen patients 
had an elevated GGT (this was the only abnormality 
in 5); 8 had a GGT elevation accompanied by an 
elevated AST or ALT. Two had an elevated GGT and an 
elevated CK with normal AST and ALT. Five patients 
had elevation of GGT on more than one visit. The vast 
majority of elevations were less than twice the top 
normal value. Highest levels were AST 191, ALT 118, 
GGT 102.
Fifty-two patients had a single episode of elevated CK 
of which 22 were female. However, 57 had multiple 
CK elevations and only one was female. Thirty-five 
patients had CK elevations less than 2 times normal; 
38 had levels between 2 and 3 times normal, 18 had 
Abstract
Current laboratory monitoring may not be optimal. 
A retrospective chart review was performed on the 
laboratory results of 246 patients who were treated 
with isotretinoin for acne over a 9-year period. Tests 
obtained were CBC, lipid panel, AST, ALT, CK, GGT, 
and C-reactive protein. Thirty-five patients had an 
elevated AST and 35 of these had an elevated CK; 32 
had an elevated ALT and 11 of these had an elevated 
CK. Thirteen patients had an elevated GGT; in 5 this 
was the only abnormality, whereas 8 had a GGT 
elevation accompanied by an elevated AST or ALT. 
Two had an elevated GGT and an elevated CK with 
normal AST and ALT. Fifty-two patients had a single 
episode of elevated CK, of which 22 were female. 
However, 57 had multiple CK elevations and only one 
was female. Thirty-five patients had CK elevations < 
2 times normal; 38 had levels between 2 and 3 times 
normal, 18 had levels between 3 and 4 times normal, 
and 18 had levels greater than 4 times normal. We 
suggest that ALT and AST are not useful for monitoring 
isotretinoin therapy and that GGT and CK may be of 
greater value in managing patients.
Volume 23 Number 5 | May 2017 
DOJ 23 (5): 12
- 2 - 
Dermatology Online Journal  ||  Case Presentation
levels between 3 and 4 times normal, and 18 had 
levels greater than 4 times normal.
Thirty-nine individuals had CRP elevations. Ten were 
elevated at baseline and 23 had elevation at the end 
of therapy. Twenty-seven patients had simultaneous 
elevations of TG and CRP.
Ninety-five patients overall had elevation of TG; 26 
were elevated at baseline, 45 had elevations at the 
end of therapy and 15 were elevated throughout 
therapy.
One hundred-eleven had elevations of cholesterol; 
45 were elevated at baseline, 75 were elevated at the 
end of therapy, and 35 had elevations throughout 
therapy.
Twenty-one had high WBC at some point in therapy; 
15 also had high ANC, two of which had a low ALC. 
Thirty patients had an episode of low WBC; 14 had 
low ANC, two of which had a high ALC and one 
had low WBC and high ANC. Modest elevations 
and depressions in hemoglobin were seen in many 
patients sporadically. Sixteen patients had elevations 
in platelets at some time during therapy; 6 of these 
were elevated on more than one occasion. No platelet 
elevation exceeded 480. Fifteen patients displayed a 
low platelet count on at least one occasion during 
therapy. The lowest value was 89, which returned to 
normal on subsequent tests. Three patients had more 
than one low level during therapy.
Case Discussion
Laboratory abnormalities during isotretinoin therapy 
are thought to be a common occurrence, but there 
is surprisingly little organized study regarding their 
severity or consequence. Zane and colleagues 
[2] studied the laboratory results of over 13,000 
isotretinoin treated patients and found 11% had 
modest transaminase elevations but nearly 50% 
had triglyceride abnormalities at some time during 
therapy. A recent study by Lee and colleagues [3] 
reported on the mean elevation of blood tests and 
found it to be low and suggested that routine testing 
may not be cost effective.
In our practice we monitor CBC, AST, ALT, GGT, CK, 
and lipids and order tests at baseline and with each 
dosage change. Peak isotretinoin dosage is typically 
near 1mg/kg. Tests that are abnormal are followed 
until they normalize. Patients are counselled on the 
significance of each abnormal test and steps that 
should be taken.
AST and ALT are enzymes thought of as “liver tests” 
but they are not liver-specific, being found in liver, 
muscle, and other tissues including red blood cells. 
GGT is a liver specific enzyme. CK is a muscle specific 
enzyme. In the current study we found that AST 
elevation was usually accompanied by CK elevation, 
suggesting a muscle (rather than liver) source for 
the AST. ALT was less strongly paired with CK but 
there was some overlap. GGT elevation was much 
less common and occurred only 13 times. These 
findings suggest that AST and ALT are less useful 
for monitoring liver damage than GGT and may be 
redundant tests. In addition, the presence of AST and 
ALT in red blood cells can lead to false positive values 
if there is hemolysis [4].
The low incidence and severity of abnormal liver tests 
(indicated by GGT level) is encouraging and suggests 
that isotretinoin is not a major cause of liver injury. It 
must also be noted that other events such as alcohol 
ingestion or infection can cause elevations in GGT 
independent of isotretinoin.
Lee et al. [3] noted the low mean severity of liver 
abnormalities and suggested that measuring AST 
and ALT may not be cost–effective. This report 
confirms that individual liver tests (as opposed to the 
mean of a large group as was measured in [3]) are 
not usually abnormal and that when elevated they 
are only mildly-so. Moreover we show that much of 
the AST and ALT elevations appear to arise from non-
liver sources.
In contrast to liver tests, muscle tests were more 
commonly elevated and some to quite high levels. In 
many cases the patients had no muscular symptoms 
but most gave a history of vigorous exercise. Men 
were at clearly greater risk of repeated elevation, 
which may reflect behavior. The significance of 
these abnormalities in CK is uncertain. CK elevations 
greater than five times normal accompanied by 
muscle pain, fatigue, and weakness can be a sign of 
rhabdomyolysis, which can lead to renal damage [6]. 
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The patients in this study did not have CK elevations 
of that magnitude.
There are two reported cases of full-blown 
rhabdomyolysis in the setting of isotretinoin therapy 
[7, 8] and patients treated with the drug commonly 
report decreased exercise tolerance and achiness[1, 
9]. Several studies have reported CK elevations from 
5 to 41% in patients treated with isotretinoin [6]. We 
counsel patients to avoid strenuous exercise during 
therapy and await further study on the effects of 
isotretinoin on muscle.
Conclusion
What tests should be used to monitor patients 
treated with isotretinoin? Clearly HCG and lipids must 
be monitored, and based on this chart review, CBC 
appears to be of minimal value. In this population, 
elevations in AST and ALT were found to not usually 
be indicative of liver problems. If the liver is to be 
monitored, GGT appears to be a more useful test. 
Given the frequency and magnitude of CK elevations 
it may be helpful, especially in the physically active, 
to monitor this enzyme during isotretinoin therapy.
Abbreviations
ALC-absolute lymphocyte count
ALT-alanine aminotransferase
ANC-absolute neutrophil count
AST-aspartate aminotransferase
CBC-complete blood count
CK-creatine kinase
GGT-gamma glutamyltransferase
TG-triglyceride
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